Evaluating the implementation of the 20-valent pneumococcal conjugate vaccine for paediatric immunization in Australia

20251 citationsJournal Articlehybrid Open Access

Authors

Aleksandar Ilić · Pfizer (United Kingdom)

Abstract

This cost-effectiveness analysis estimated that adoption of PCV20 into the Australian paediatric NIP would be dominant versus PCV13 and PCV15, leading to health benefits and cost-savings.

Topics & Keywords

Pneumonia and Respiratory Infections Respiratory viral infections research Advanced Causal Inference Techniques

Publication Details

Published in: Vaccine

Volume 69, pp. 127996-127996

DOI: 10.1016/j.vaccine.2025.127996

Field-Weighted Citation Impact: 1.54

Command Palette

Evaluating the implementation of the 20-valent pneumococcal conjugate vaccine for paediatric immunization in Australia

Authors

Abstract

Topics & Keywords

Publication Details